BACKGROUND AND PURPOSE: Direct comparison of symptomatic intracerebral hemorrhage (sICH) rates among different thrombolysis studies is complicated by the variability of definitions of sICH. The prediction of outcome still remains unclear. METHODS: Baseline data and clinical courses of patients treated with thrombolytic therapy were collected in a prospective database. The 3-month outcome was evaluated using the modified Rankin Scale. Results of 24-hour follow-up imaging were reevaluated by at least 2 independent raters. Four common definitions of sICH (National Institute of Neurological Disorders and Stroke [NINDS], European Cooperative Acute Stroke Study [ECASS] 2, Safe Implementation of Thrombolysis in Stroke [SITS], ECASS 3) were applied. Kappa interrater statistics were calculated. Our objective was to find the sICH definition with the highest predictive value for mortality, poor (modified Rankin Scale 5 or 6) and unfavorable (modified Rankin Scale ≥3) clinical outcome after 90 days. RESULTS: The data of 314 patients were analyzed. The NINDS definition revealed the highest sICH rate (7.7%); the lowest rate was found for the ECASS 3 definition (3.2%) of sICH. The highest interrater agreement was found for the ECASS 2 definition (κ 0.85) and the lowest for the NINDS definition (κ 0.57). Patients with sICH according to the SITS definition had the highest risk for death (OR, 14.4) and poor outcome (OR, 26.6). CONCLUSIONS: None of the different definitions contains an optimal combination of prediction of mortality and outcome and a high interrater agreement rate. For the clinical evaluation of mortality, we recommend using the SITS definition; for studies needing a high interrater agreement rate, we recommend using the ECASS 2 definition. Due to the lack of 1 single optimal definition, future thrombolytic trials should preferably use different definitions.
BACKGROUND AND PURPOSE: Direct comparison of symptomatic intracerebral hemorrhage (sICH) rates among different thrombolysis studies is complicated by the variability of definitions of sICH. The prediction of outcome still remains unclear. METHODS: Baseline data and clinical courses of patients treated with thrombolytic therapy were collected in a prospective database. The 3-month outcome was evaluated using the modified Rankin Scale. Results of 24-hour follow-up imaging were reevaluated by at least 2 independent raters. Four common definitions of sICH (National Institute of Neurological Disorders and Stroke [NINDS], European Cooperative Acute Stroke Study [ECASS] 2, Safe Implementation of Thrombolysis in Stroke [SITS], ECASS 3) were applied. Kappa interrater statistics were calculated. Our objective was to find the sICH definition with the highest predictive value for mortality, poor (modified Rankin Scale 5 or 6) and unfavorable (modified Rankin Scale ≥3) clinical outcome after 90 days. RESULTS: The data of 314 patients were analyzed. The NINDS definition revealed the highest sICH rate (7.7%); the lowest rate was found for the ECASS 3 definition (3.2%) of sICH. The highest interrater agreement was found for the ECASS 2 definition (κ 0.85) and the lowest for the NINDS definition (κ 0.57). Patients with sICH according to the SITS definition had the highest risk for death (OR, 14.4) and poor outcome (OR, 26.6). CONCLUSIONS: None of the different definitions contains an optimal combination of prediction of mortality and outcome and a high interrater agreement rate. For the clinical evaluation of mortality, we recommend using the SITS definition; for studies needing a high interrater agreement rate, we recommend using the ECASS 2 definition. Due to the lack of 1 single optimal definition, future thrombolytic trials should preferably use different definitions.
Authors: Philipp Bücke; Marta Aguilar Pérez; Elisabeth Schmid; Christian H Nolte; Hansjörg Bäzner; Hans Henkes Journal: Clin Neuroradiol Date: 2017-01-31 Impact factor: 3.649
Authors: Raul G Nogueira; Rishi Gupta; Tudor G Jovin; Elad I Levy; David S Liebeskind; Osama O Zaidat; Ansaar Rai; Joshua A Hirsch; Daniel P Hsu; Marilyn M Rymer; Ashis H Tayal; Ridwan Lin; Sabareesh K Natarajan; Ashish Nanda; Melissa Tian; Qing Hao; Junaid S Kalia; Michael Chen; Alex Abou-Chebl; Thanh N Nguyen; Albert J Yoo Journal: J Neurointerv Surg Date: 2014-01-08 Impact factor: 5.836
Authors: Joshua A Stone; Joshua Z Willey; Salah Keyrouz; James Butera; Ryan A McTaggart; Shawna Cutting; Brian Silver; Bradford Thompson; Karen L Furie; Shadi Yaghi Journal: Curr Treat Options Neurol Date: 2017-01 Impact factor: 3.598
Authors: David Asuzu; Karin Nyström; Hardik Amin; Joseph Schindler; Charles Wira; David Greer; Nai Fang Chi; Janet Halliday; Kevin N Sheth Journal: Neurocrit Care Date: 2015-10 Impact factor: 3.210
Authors: David Asuzu; Karin Nyström; Hardik Amin; Joseph Schindler; Charles Wira; David Greer; Nai Fang Chi; Janet Halliday; Kevin N Sheth Journal: Neurocrit Care Date: 2015-12 Impact factor: 3.210
Authors: David Asuzu; Karin Nystrom; Hardik Amin; Joseph Schindler; Charles Wira; David Greer; Nai Fang Chi; Janet Halliday; Kevin N Sheth Journal: Neurocrit Care Date: 2015-04 Impact factor: 3.210